Encelto (revakinagene taroretcel-lwey) / Neurotech Pharma - LARVOL DELTA

NT-501 Capsule Stability and Encapsulated Cell Technology Platform Capabilities (ASGCT 2025) - "The simulated in vivo stability study supports that the NT-501 capsule remains integral and the capsule materials are stable for at least two years. Additionally, modifications can be made to the ECT capsule to alter the delivery levels or targets of therapeutics making it a versatile long term delivery platform for intraocular diseases. Disease Focus of Abstract:Ophthalmic Diseases"

Ophthalmology

Sustained Drug Delivery of Ciliary Neurotrophic Factor by Encapsulated Cell Technology: NT-501 Implants: (ASGCT 2025) - "Neurotech's ECT was developed to overcome the challenge of long-term therapeutic delivery to the retina. NT-501 consists of an encapsulated cell line that has been genetically engineered to produce a novel secreted form of human CNTF. Extensive characterization was conducted across product shelf life, stability, and on explanted devices which were implanted for up to 14.5 years."

Ophthalmology

Revakinagene taroretcel (Encelto) - a gene therapy for idiopathic macular telangiectasia. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Gene Therapies • Ophthalmology

Neuroprotective Characteristics of CNTF Delivered by Encapsulated Cells for the Treatment of Degenerative Diseases of the Retina (ARVO 2025) - "Purpose Neurotech's proprietary encapsulated cell therapy (ECT) utilizes a genetically engineered cell line, NTC-201.6A, to deliver ciliary neurotrophic factor (CNTF) to the retina...CNTF is a protein with demonstrated neuroprotective capabilities. We have analyzed CNTF that is delivered by encapsulated cells and shown that it retains expected activity and characteristics."

Ophthalmology

Determining the function of NT-501 produced CNTF at physiological levels in human retinas. (ARVO 2025) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Ophthalmology

Pharmacokinetics and Bioavailability of CNTF following Intraocular Implant of Encapsulated Cell Therapy (ECT) in NZW Rabbits (ARVO 2025) - "Each device contained an encapsulated cell line (NTC-201-6A) genetically engineered to secrete CNTF...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

PK/PD data • Preclinical • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Glaucoma • Ocular Inflammation • Ophthalmology

A Study to Determine the Safety and Efficacy of NT-501 With MHFM (clinicaltrials.gov) - P3 | N=13 | Recruiting | Sponsor: Neurotech Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Ophthalmology

Neurotech’s ENCELTO (revakinagene taroretcel-lwey) Approved by the FDA for the Treatment of Macular Telangiectasia Type 2 (MacTel) (Businesswire) - "Neurotech Pharmaceuticals...announced that the U.S. Food and Drug Administration (FDA), has approved ENCELTO (revakinagene taroretcel-lwey) for the treatment of Macular Telangiectasia type 2 (MacTel)....The approval was based on results from two phase 3 trials which demonstrated that after placement, of the implant, ENCELTO significantly slowed the loss of macular photoreceptors in MacTel patients over 24 months. ENCELTO is expected to be available in the United States for patients starting in June of 2025."

FDA approval • Launch US • Ophthalmology

Ciliary Neurotrophic Factor Implant in Geographic Atrophy from Age-related Macular Degeneration: A Long-Term Case Study. (PubMed, Retin Cases Brief Rep) - "Notably, the implanted eye, exhibited less progression of macular GA and peripapillary atrophy. While acknowledging the limitations of a single case, we highlight the potential benefits of using the CNTF implant, a one-time surgical procedure, in reducing the treatment burden for atrophic AMD patients. We hope to see further reports from other sites that participated in this compassionate use protocol for NT-501 in atrophic AMD."

Journal • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel) (Businesswire) - "Neurotech Pharmaceuticals, Inc...announced that the U.S. Food and Drug Administration (FDA), has extended the Prescription Drug User Fee Act (PDUFA) goal date by three months to allow time required for the FDA to review additional data provided by the Company in response to recent requests from the FDA. The new PDUFA goal date for the biologics license application (BLA) of NT-501 (revakinagene taroretcel) as a treatment for Macular telangiectasia type 2 (MacTel) is March 18, 2025."

PDUFA • Ophthalmology

Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration (clinicaltrials.gov) - P2 | N=54 | Active, not recruiting | Sponsor: Stanford University | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Aug 2024 ➔ Aug 2025

Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

Pooled Visual Function Data of Neurotrophic Factor–Producing Revakinagene Taroretcel in People With Macular Telangiectasia Type 2 (AAO 2024) - No abstract available

Late-breaking abstract • Ophthalmology

A Randomized, Sham Controlled, Masked Phase 2 Study for Safety of Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for the Treatment of Glaucoma: Adverse Events and Structural Outcomes (AAO 2024) - P2 | "Conclusions The NT-501 implant is safe in glaucoma patients, with structural enhancement suggesting biological activity. HVF efficacy analysis is pending."

Adverse events • Clinical • P2 data • Glaucoma • Ophthalmology

Pooled Clinical Trial Safety Data of Neurotrophic Factor–Producing Revakinagene Taroretcel in People With MacTel2 (AAO 2024) - "Conclusion NT-501 was well tolerated; most ocular TEAEs were mild and transient. Few serious ocular TEAEs occurred, and most were surgery related and expected."

Clinical • Ophthalmology

Ciliary Neurotrophic Factor Secreted by NT-501 Encapsulated Cell Technology in Patients With Retinal Degenerative Disorders (AAO 2024) - P1, P2 | "CNTF and anti-CNTF and encapsulated cell antibodies were not detected in any participant's serum. Conclusion Intraocular NT-501 may be a long-term treatment option for retinal degenerative diseases."

Clinical • Age-related Macular Degeneration • Inherited Retinal Dystrophy • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Long-Term Safety and Efficacy of Revakinagene Taroretcel (NT-501) Ciliary Neurotrophic Factor Implant for MacTel2 (AAO 2024) - "Most (95%) ocular TEAEs across cohorts were of mild or moderate severity. Conclusion NT-501 was generally well tolerated 72 to 108 months after intraocular implantation."

Clinical • Ophthalmology

Revakinagene Taroretcel for Macular Telangiectasia Type 2 (Phase 3 NTMT-03-A and NTMT-03-B Studies) (AAO 2024) - No abstract available

P3 data • Ophthalmology

Safety Study of Bilateral Revakinagene Taroretcel in Participants With MacTel2 (AAO 2024) - P2 | "Conclusion Bilateral NT-501 implantation was generally safe and well tolerated 6 months postimplantation. We did not detect new risk with bilateral NT-501 in MacTel."

Clinical • Ophthalmology • DHFR

Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Stanford University | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Aug 2024 ➔ Aug 2025

Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

Neurotech Pharmaceuticals, Inc. Receives Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel) (Businesswire) - "Neurotech Pharmaceuticals, Inc...announces that the U.S. Food and Drug Administration (FDA), has determined that the Biologic License Application (BLA) for NT-501, an investigational encapsulated cell therapy for the treatment of MacTel, is sufficiently complete to permit a substantive review. The application has a prescription drug user fee act (PDUFA) goal date of December 17, 2024."

FDA filing • PDUFA • Priority review • Ophthalmology • Retinal Disorders

A Study to Determine the Safety and Efficacy of NT-501 With MHFM (clinicaltrials.gov) - P3 | N=13 | Not yet recruiting | Sponsor: Neurotech Pharmaceuticals | Trial completion date: Dec 2025 ➔ Jul 2026 | Initiation date: Jul 2024 ➔ Apr 2025 | Trial primary completion date: Sep 2025 ➔ Apr 2026

Trial completion date • Trial initiation date • Trial primary completion date • Ophthalmology

A Study to Determine the Safety and Efficacy of NT-501 With MHFM (clinicaltrials.gov) - P3 | N=13 | Not yet recruiting | Sponsor: Neurotech Pharmaceuticals

New P3 trial • Ophthalmology

Hydrolytic Stability and Seal Integrity Evaluation of the NT-501 Capsule and Capsule Component Materials (ARVO 2024) - "The stability study supports that the NT-501 capsule remains integral throughout the intended implant period of two years."

Ophthalmology

Immunogenicity Analysis of the NT-501 Intraocular Implant on a Cohort of Study Participants (ARVO 2024) - "These data suggest that patients did not mount an immune response to NT-501, and that the presence of antibodies is not treatment related. Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details.: A study was performed to determine if the immune system reacted against the NT-501 intraocular implant."

Ophthalmology • DHFR

A Randomized, Sham Controlled, Masked Phase II Study for Safety of Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for the Treatment of Glaucoma: Adverse Events and Structural Outcomes (ARVO 2024) - P2 | "The NT-501 implant demonstrated an excellent safety profile in glaucoma patients, with promising structural enhancement indicating biological activity. Further analysis of HVF efficacy will follow."

Adverse events • Clinical • P2 data • Glaucoma • Ophthalmology